Patents by Inventor Marc Adler

Marc Adler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
    Patent number: 11643388
    Abstract: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 9, 2023
    Assignees: The Regents of the University of California, ShangPharma Innovation Inc.
    Inventors: Dean Sheppard, William F. DeGrado, Aparna Sundaram, Hyunil Jo, Richard Beresis, Marc Adler
  • INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF
    Publication number: 20220411366
    Abstract: Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 29, 2022
    Inventors: Dean Sheppard, William F. DeGrado, Aparna Sundaram, Hyunil Jo, Richard Beresis, Marc Adler
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20220324814
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: April 12, 2022
    Publication date: October 13, 2022
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Calpain modulators and therapeutic uses thereof
    Patent number: 11339130
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: May 24, 2022
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Calpain modulators and therapeutic uses thereof
    Patent number: 11292801
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic ?-keto amide derivatives and their use as therapeutic agents.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 5, 2022
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210347727
    Abstract: Small molecule calpain modulator compositions and pharmaceutical compositions can be prepared and used as therapeutic agents. Exemplary compositions include non-macrocyclic a-keto amide derivatives. The therarapeutic agents can be used for treating fibrotic disease or a resulting secondary disease state or condition. The small molecules can competitively bind with calpastatin and/or inhibit calpain through contact with CAPN1, CAPN2, and/or CAPN9 enzymes.
    Type: Application
    Filed: June 19, 2018
    Publication date: November 11, 2021
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • STRAD-binding agents and Uses Thereof
    Publication number: 20210261587
    Abstract: Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Inventors: John Gordan, Dominique Mitchell, Richard Beresis, Marc Adler
  • VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210238192
    Abstract: Disclosed herein are small molecule Vascular Adhesion Protein-1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: June 27, 2019
    Publication date: August 5, 2021
    Inventors: Brad Owen Buckman, Prabha Ibrahim, Shendong Yuan, Kumaraswamy Emayan, Marc Adler
  • Calpain modulators and therapeutic uses thereof
    Patent number: 10934261
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 2, 2021
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • Calpain modulators and therapeutic uses thereof
    Patent number: 10894776
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: January 19, 2021
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler, Kumaraswamy Emayan, Jingyuan Ma
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210009564
    Abstract: Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 14, 2021
    Inventors: Brad Owen Buckman, Shendong Yuan, Kumaraswamy Emayan, Marc Adler, Prabha Ibrahim
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20200392157
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic ?-keto amide derivatives and their use as therapeutic agents.
    Type: Application
    Filed: June 29, 2017
    Publication date: December 17, 2020
    Inventors: Brad Owen Buckman, Shendong Yuan, John Beamond Nicholas, Jingyuan Ma, Kumaraswamy Emayan, Marc Adler
  • Articles with soil-shedding performance
    Patent number: 10675609
    Abstract: An article of manufacture has an external surface at least partly defined by a material compositionally comprising a polymeric hydrogel that takes up water when wetted. The hydrogel-containing material is effective in reducing soil accumulation on, and/or for reducing soil adhesion to, an article designed for a variety of uses, such as transportation, vehicle safety, storage, recreation, leisure, waste disposal, construction, gardening, or traffic control.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: June 9, 2020
    Assignee: NIKE, INC.
    Inventors: Hossein A. Baghdadi, Caleb W. Dyer, Myron Maurer, Denis Schiller, Jeremy D. Walker, Zachary C. Wright, Marc Adler
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20200123114
    Abstract: Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 23, 2020
    Applicant: Blade Therapeutics, Inc.
    Inventors: Brad Owen BUCKMAN, John Beamond NICHOLAS, Shendong YUAN, Marc ADLER, Kumaraswamy EMAYAN, Jingyuan MA
  • Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
    Patent number: 10590084
    Abstract: The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 17, 2020
    Assignee: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler
  • CYCLIC KETO-AMIDE COMPOUNDS AS CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF
    Publication number: 20190194139
    Abstract: The present technology relates to cyclic keto-amide compounds of general formulae I to XXXII, compositions and kits thereof as calpain modulators and methods useful for the treatment of various diseases or disorders such as fibrotic disease or cancer which are associated or mediated, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is also applicable to cyclic keto-amide compounds which inhibit myofibroblast differentiation.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 27, 2019
    Applicant: Blade Therapeutics, Inc.
    Inventors: Brad Owen Buckman, John Beamond Nicholas, Shendong Yuan, Marc Adler
  • Therapeutic compounds and uses thereof
    Patent number: 10202378
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: February 12, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • Substituted cinnolines as inhibitors of LRRK2 kinase activity
    Patent number: 9884828
    Abstract: The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: February 6, 2018
    Assignee: Imago Pharmaceuticals, Inc.
    Inventors: Danielle L. Aubele, Albert W. Garofalo, Simeon Bowers, Anh P. Truong, Xiaocong Michael Ye, Maurizio Franzini, Marc Adler, R. Jeffrey Neitz, Gary Probst
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20180009805
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.
    Type: Application
    Filed: July 24, 2017
    Publication date: January 11, 2018
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Daniel J. Burdick, Terry Crawford, Martin Duplessis, Steven R. Magnuson, Christopher G. Nasveschuk, Anthony F. Romero, Yong Tang, Vickie Hsiao-Wei Tsui, Shumei Wang
  • THERAPEUTIC COMPOUNDS AND USES THEREOF
    Publication number: 20170333406
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: August 2, 2017
    Publication date: November 23, 2017
    Applicants: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu